Oncolytics expands enrollment for cancer drug late-stage trial

(Reuters) - Oncolytics Biotech Inc said it expanded enrollment in a late-stage study testing its head and neck cancer drug to determine its effects on two distinct patient groups.

via Reuters: Health News Read More Here..